After reading the 2012-2013 Economic Report on the Pharmaceutical Wholesalers, we felt compelled to share this information as TurningPoint is in the business of improving financial results in the Pharmaceutical Wholesaler industry.
This article will provide you with an overview of wholesalers key business strategies and how they are gaining financial stability. Below is a preview of the article:
The $300 billion U.S. drug wholesaling industry is evolving faster than ever. The biggest wholesalers are positioning themselves as indispensable intermediaries in the supply chain and staking out a powerful position in high-growth channels for specialty drugs. In 2011, the largest wholesalers grew faster than did manufacturers or retail pharmacies. Understanding wholesalers’ strategies and finances has never been more crucial.
The completely updated, revised, and expanded 2012–13 Economic Report on Pharmaceutical Wholesalers gives you a comprehensive overview and analysis of the latest financial and industry data. The report was researched and written by Adam. J. Fein, Ph.D., one of the world’s leading experts on the industry and author of the influential Drug Channels website. Dr. Fein synthesized a wealth of statistical data (including 62 data-packed exhibits), research studies, financial information, and his own unique business consulting experience into a definitive, nonpartisan resource.
Key areas of review
- Identify the key participants in the drug wholesaling industry
- Explain the services provided by wholesalers to pharmacies, hospitals, and manufacturers
- Distinguish among the different wholesalers’ services provided to larger and smaller pharmacies
- Describe the evolving sources of wholesaler compensation and profits
- Delineate the sources and uses of cash generated by wholesalers’ business operations
- Define the key industry trends affecting the wholesale industry
- Assess differences among the Big Three wholesalers’ business performance
The many new sections in the 2012-13 edition include: an overview of wholesaler key business strategies; a new chapter examining financial stability at the largest companies; information on wholesalers’ role in the 340B discount program; new content regarding pedigree and supply chain enforcement; profit estimates throughout the generic drug lifecycle; additional analysis of top customers; and much more. The report also provides detailed company analysis of the Big Three public wholesalers: AmerisourceBergen, McKesson, and Cardinal Health.
Read on: http://www.pembrokeconsulting.com/wholesale.html
